HTB

Treatment strategies

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

Dolutegravir-based dual therapy as switch option in multiple studies

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART

Increased risk of IRIS with integrase inhibitors reported in two studies

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

Four day a week ART: sub-optimal drug levels but few virological failures

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

Further results using dolutegravir monotherapy: urgent need for controlled studies

Potential economic impact of dolutegravir/3TC dual therapy

First-line ART with dolutegravir plus 3TC: 24-week early results

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

Four reasons IAS 2015 will be a milestone HIV conference: a personal view

Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study

The option for same day antiretroviral therapy on diagnosis: the future model for HIV care

Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA

HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Gender differences in use of cardiovascular disease-related interventions: D:A:D study

Higher ART coverage is associated with lower HIV infection rates in a multi-country analysis

No difference in overall anaemia rate with reduced dose AZT

Fit for purpose: treatment optimisation 2014

50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice

PIVOT study: further analysis from five-year PI/r monotherapy strategy study

Hospitalisation among elite controllers

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

Southern African treatment guidelines retain CD4 threshold of 350 for starting ART

Executive summary and research policy recommendations

Retrofitting for purpose: treatment optimisation 2013

The tuberculosis treatment pipeline

Why the “when to start” question is complex and informed by limited evidence: a response to Dr Myron Cohen

START study increases sample size: additional 600 participants to be older than 35

Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily

Switching boosted-PIs to raltegravir

Scaling up: what to do first?

Tablets more acceptable than syrups in the ARROW trial

Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999

HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in patients interrupting treatment in the SMART trial: new study to randomise patients with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3

CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r

Autologous stem cells transplant (ASCT) in HIV-positive individuals with a relapsed non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD)

Treatment interuption arm in DART trial is stopped early

Simplification to atazanavir/ritonavir monotherapy

Summary of STI studies: SMART shows clear increased risk from interrupting treatment at any CD4 count

Treatment in primary HIV infection

Therapeutic vaccinations and treatment interruptions

Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)

Another chance for 3TC in patients with M184V mutation?

Kaletra monotherapy: small studies and early data

Interruption of treatment is safe for those who started too early

STIs in resource limited settings

Studies and strategies with existing drugs

Treatment interruption prior to five-drug regime shows no benefit at 48 weeks

Failure of alternating week-on and week-off therapy

Post navigation